{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:31:04Z","timestamp":1788438664961,"version":"build-2803163510"},"reference-count":23,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Amgen Ltd","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,4,13]]},"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Objective<\/jats:title>\n                  <jats:p>To assess use of bone-targeting agents (BTA) in patients with confirmed bone metastases (BM) from breast cancer (BC), non-small cell lung cancer (NSCLC) or prostate cancer (PC).<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Regional hospital-based oncology database of approximately 2\u2009million patients in England.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients aged \u226518 years with a diagnosis of BC, NSCLC or PC as well as BM between 1 January 2007 and 31 December 2018, with follow-up to 30 June 2020 or death; BM diagnosis ascertained from recorded medical codes and unstructured data using natural language processing (NLP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcomes measures<\/jats:title>\n                    <jats:p>Initiation or non-initiation of BTA following BM diagnosis, time from BM diagnosis to BTA initiation, time from first to last BTA, time from last BTA to death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 559 BC, 894 NSCLC and 1013 PC with BM; median age (Q1\u2013Q3) was 65 (52\u201376), 69 (62\u201377) and 75 (62\u201377) years, respectively. NLP identified BM diagnosis from unstructured data for 92% patients with BC, 92% patients with NSCLC and 95% patients with PC. Among patients with BC, NSCLC and PC with BM, 47%, 87% and 88% did not receive a BTA, and 53%, 13% and 12% received at least one BTA, starting a median 65 (27\u2013167), 60 (28\u2013162) and 610 (295\u2013980) days after BM, respectively. Median (Q1\u2013Q3) duration of BTA treatment was 481 (188\u2013816), 89 (49\u2013195) and 115 (53\u2013193) days for patients with BC, NSCLC and PC. For those with a death record, median time from last BTA to death was 54 (26\u2013109) for BC, 38 (17\u201398) for NSCLC and 112 (44\u2013218) days for PC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study identifying BM diagnosis from both structured and unstructured data, a high proportion of patients did not receive a BTA. Unstructured data provide new insights on the real-world use of BTA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-069214","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T11:39:15Z","timestamp":1683545955000},"page":"e069214","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2997-5867","authenticated-orcid":false,"given":"Anouchka","family":"Seesaghur","sequence":"first","affiliation":[{"name":"Centre for Observational Research, Amgen Ltd Uxbridge, Uxbridge, Middlesex, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8819-6700","authenticated-orcid":false,"given":"Peter","family":"Egger","sequence":"additional","affiliation":[{"name":"Real World Studies, IQVIA Europe, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Warden","sequence":"additional","affiliation":[{"name":"Real World Studies, IQVIA Europe, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Abbasi","sequence":"additional","affiliation":[{"name":"Centre for Observational Research, Amgen Ltd Uxbridge, Uxbridge, Middlesex, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Levick","sequence":"additional","affiliation":[{"name":"Real World Studies, IQVIA Europe, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Riaz","sequence":"additional","affiliation":[{"name":"Real World Studies, IQVIA Europe, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McMahon","sequence":"additional","affiliation":[{"name":"Real World Studies, IQVIA Europe, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Thompson","sequence":"additional","affiliation":[{"name":"Real World Studies, IQVIA Europe, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Cheeseman","sequence":"additional","affiliation":[{"name":"REAL Oncology, The Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"key":"2025121407064542000_13.5.e069214.1","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2017.715","article-title":"Bone metastasis risk factors in breast cancer","volume":"11","author":"Pulido","year":"2017","journal-title":"Ecancermedicalscience"},{"key":"2025121407064542000_13.5.e069214.2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S155524"},{"key":"2025121407064542000_13.5.e069214.3","doi-asserted-by":"crossref","unstructured":"Santini D , Barni S , Intagliata S , et al . Natural history of non-small-cell lung cancer with bone metastases. Sci Rep 2015;5. doi:10.1038\/srep18670","DOI":"10.1038\/srep18670"},{"key":"2025121407064542000_13.5.e069214.4","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014521110"},{"key":"2025121407064542000_13.5.e069214.5","doi-asserted-by":"crossref","unstructured":"Liu D , Kuai Y , Zhu R , et al . n.d. Prognosis of prostate cancer and bone metastasis pattern of patients: a SEER-based study and a local hospital based study from China. Sci Rep;10. doi:10.1038\/s41598-020-64073-6","DOI":"10.1038\/s41598-020-64073-6"},{"key":"2025121407064542000_13.5.e069214.6","article-title":"Bone metastases: an overview","volume":"11","author":"Macedo","year":"2017","journal-title":"Oncol Rev"},{"key":"2025121407064542000_13.5.e069214.7","first-page":"335","article-title":"Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States","volume":"7","author":"Hernandez","year":"2015","journal-title":"Clin Epidemiol"},{"key":"2025121407064542000_13.5.e069214.8","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1002\/cam4.4027","article-title":"Cardiovascular events in cancer patients with bone metastases-A Danish population-based cohort study of 23,113 patients","volume":"10","author":"Asdahl","year":"2021","journal-title":"Cancer Med"},{"key":"2025121407064542000_13.5.e069214.9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049831","article-title":"Risk of infections and mortality in Danish patients with cancer diagnosed with bone metastases: a population-based cohort study","volume":"11","author":"Hjelholt","year":"2021","journal-title":"BMJ Open"},{"key":"2025121407064542000_13.5.e069214.10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu103"},{"key":"2025121407064542000_13.5.e069214.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.019"},{"key":"2025121407064542000_13.5.e069214.12","unstructured":"Overview | denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours | guidance | (NICE). 2012."},{"key":"2025121407064542000_13.5.e069214.13","doi-asserted-by":"crossref","unstructured":"Jensen A\u00d8 . n.d. Validity of the recorded International classification of diseases, 10th edition diagnoses codes of bone metastases and skeletal-related events in breast and prostate cancer patients in the Danish national Registry of patients. CLEP;1:101. doi:10.2147\/CLEP.S5446","DOI":"10.2147\/CLEP.S5446"},{"key":"2025121407064542000_13.5.e069214.14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/CLEP.S92209","article-title":"Validation of international classification of diseases coding for bone metastases in electronic health records using technology-enabled abstraction","volume":"7","author":"Liede","year":"2015","journal-title":"Clin Epidemiol"},{"key":"2025121407064542000_13.5.e069214.15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/M18-0543","article-title":"ESPACOMP medication adherence reporting guideline (emerge)","volume":"169","author":"De Geest","year":"2018","journal-title":"Ann Intern Med"},{"key":"2025121407064542000_13.5.e069214.16","unstructured":"Team RC . A language and environment for statistical computing. R foundation for statistical computing. Vienna, Austria:; 2022. Available: https:\/\/www.R-project.org\/"},{"key":"2025121407064542000_13.5.e069214.17","doi-asserted-by":"crossref","unstructured":"von Moos R , Lewis K , Massey L , et al . Initiation of bone-targeted agents in patients with bone metastases and breast or castrate-resistant prostate cancer actively treated in routine clinical practice in Europe. Bone 2022;154. doi:10.1016\/j.bone.2021.116243","DOI":"10.1016\/j.bone.2021.116243"},{"key":"2025121407064542000_13.5.e069214.18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2017.03.031","article-title":"Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer-results from the prospective German tumour Registry breast cancer cohort study","volume":"79","author":"Schr\u00f6der","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025121407064542000_13.5.e069214.19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/pds.4360","article-title":"Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States","volume":"27","author":"Butler","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121407064542000_13.5.e069214.20","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2147\/CLEP.S175063","article-title":"Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US","volume":"10","author":"McGrath","year":"2018","journal-title":"Clin Epidemiol"},{"key":"2025121407064542000_13.5.e069214.21","first-page":"5223","article-title":"Real-World use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany","volume":"28","author":"Diel","year":"2020","journal-title":"Support Care Cancer"},{"key":"2025121407064542000_13.5.e069214.22","unstructured":"Snee MCS , Thompson M . Temporal trends in treatment and overall survival among patients with incident NSCLC in the UK: a REAL-oncology database analysis from the I-O optimise initiative. presented at: 9th European lung cancer Congress (ELCC) [Geneva, Switzerland]. 2019. Available: https:\/\/www.leedsth.nhs.uk\/assets\/ca7effdffd\/28.-Snee_REAL-ONC_44P_ELCC2019_FINAL-Poster_4Apr19.pdf"},{"key":"2025121407064542000_13.5.e069214.23","unstructured":"FDA Approves Denosumab for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer . Cancer Network: FDA, 2011."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-069214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:06:54Z","timestamp":1765724814000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-069214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,8]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/bmjopen-2022-069214"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-069214","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}